PTQ valuationConsidering the recovered funds and guidance towards stronger revenue in H2 2019, this stock has never been more undervalued than in the mid to high $0.70s. Im no PHD but I don’t believe that cardiovascular disease declines during recessions. It’s a recession proof sector and these guys are out to take market share from competitors.